Xanthohumol as an Adjuvant in the Treatment of Septic Shock

Launched by MEDICAL UNIVERSITY OF LUBLIN · Jan 17, 2024

Keywords

ClinConnect Summary

This clinical trial is studying a natural substance called Xanthohumol (Xn) to see if it can help patients with septic shock, a serious condition caused by severe infections that can lead to organ failure. Septic shock often affects breathing and blood circulation, making it critical for patients to receive immediate care. Xanthohumol is believed to have strong anti-inflammatory properties, which means it could help reduce the harmful effects of inflammation in the body and improve lung function. The trial is looking for participants who are in the early stages of septic shock, have breathing difficulties that require mechanical ventilation, and show signs of severe bacterial infection.

To be eligible for this trial, participants must be adults between 65 and 74 years old, and they should not have severe chronic heart, lung, or liver diseases. They also need to be experiencing specific symptoms related to septic shock and must not have an allergy to hops or their derivatives. If you or a loved one qualify and decide to participate, you can expect to receive careful monitoring and treatment with Xanthohumol, which has been shown to be safe and well-tolerated. This trial could provide valuable information on how to better manage septic shock and improve recovery for patients.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • a septic shock in the early, acute phase,
• • respiratory insufficiency required mechanical ventilation with PaO2/FiO2 \< 150,
• • bacterial infection,
• • procalcitonin higher than 5 ng/mL and interleukin 6 higher than 100 pg/mL,
• • no allergy to hops or their derivatives,
• • hemodynamic instability requiring vasopressor infusions
• Exclusion Criteria:
• • lack of agreement
• • septic shock treated for more than 1 day,
• • history of severe chronic cardiac, pulmonary and/or liver diseases